Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 9/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067181 | 0.87 | NPC1 (0.54) | CYP11B2NOTUMHDAC6ARDRD1 | |
| SCHEMBL18804932 | 0.81 | AR (0.40) | NOTUMHDAC6AR | |
| SCHEMBL15779129 | 0.77 | CASP6 (0.57) | BCAT2CYP11B1CYP11B2DRD3NPC1 | |
| SCHEMBL29163639 | 0.77 | BCAT2 (0.65) | BCAT2CYP11B1CYP11B2HDAC6DRD1 | |
| SCHEMBL29420242 | 0.77 | BCAT2 (0.65) | BCAT2CYP11B1CYP11B2HDAC6DRD1 | |
| SCHEMBL10066977 | 0.76 | AR (0.55) | NOTUMAR | |
| SCHEMBL31134807 | 0.74 | BCAT2 (0.65) | BCAT2HDAC6DRD1NPC1RAB9A | |
| SCHEMBL25209185 | 0.74 | NOTUM (0.47) | NOTUMRAB9A | |
| SCHEMBL29420232 | 0.73 | NPC1 (0.68) | BCAT2CYP11B1CYP11B2HDAC6DRD1 | |
| SCHEMBL2600444 | 0.73 | NPC1 (0.68) | BCAT2CYP11B1CYP11B2HDAC6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323813-B1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3323813-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-2654428-B1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USESE THEREOF | UNIV COLUMBIA (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170121276-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-04 | — | — | US | disclosed |
| WO-2012088420-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USESE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121276-A1 | HISTONE ACETYLTRANSFERASE MODULATORS AND USES THEREOF | EP300, KAT2A, HTT | BCAT2 636/4885CYP11B1 4657/4885CYP11B2 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.